CC
Casdin Capital Portfolio holdings
AUM
$1.2B
1-Year Est. Return
36.59%
1 Year Est. Return
+36.59%
AUM
$1.2B
AUM Growth
+$101M
(+9.2%)
Holding
38
Top Buys
| 1 | +$23.7M | |
| 2 | +$16.1M | |
| 3 | +$9.24M | |
| 4 |
Prime Medicine
PRME
|
+$8.86M |
| 5 |
UnitedHealth
UNH
|
+$8.63M |
Top Sells
| 1 | +$53.9M | |
| 2 | +$46M | |
| 3 | +$25.5M | |
| 4 |
Codexis
CDXS
|
+$17.6M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$16.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTNM
26
Contineum Therapeutics
CTNM
$335M
| $1.74M | 0.15% |
148,333
|
|
||
27
Pacific Biosciences
PACB
$583M
| $926K | 0.08% |
723,767
|
|
||
28
Recursion Pharmaceuticals
RXRX
$2.44B
| $807K | 0.07% |
165,323
|
|
||
29
Monte Rosa Therapeutics
GLUE
$1.09B
| $637K | 0.05% |
86,014
|
|
||
30
Century Therapeutics
IPSC
$58.3M
| $612K | 0.05% |
1,228,190
|
|
||
31
Tenaya Therapeutics
TNYA
$111M
| $586K | 0.05% |
361,969
|
|
||
32
Ginkgo Bioworks
DNA
$499M
| $532K | 0.04% |
36,493
|
|
||
33
Agios Pharmaceuticals
AGIO
$1.48B
| – | – |
-100,000
|
|
||
|
34
Codexis
CDXS
$145M
| – | – |
-7,200,000
|
|
||
35
Eli Lilly
LLY
$932B
| – | – |
-8,500
|
|
||
36
Syndax Pharmaceuticals
SNDX
$1.77B
| – | – |
-650,000
|
|
||
|
37
Sarepta Therapeutics
SRPT
$2.22B
| – | – |
-990,097
|
|
||
|
VERV
38
DELISTED
Verve Therapeutics
VERV
| – | – |
-4,095,571
|
|